Is GLUE or IMCR more undervalued in 2026?

CirclFi compares Monte Rosa Therapeutics, Inc. (GLUE) and Immunocore Holdings plc (IMCR) using 13 institutional-grade valuation models. GLUE has a Quality of Company score of 5.2/10 while IMCR scores 8.2/10.

Which is a better buy — GLUE or IMCR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GLUE and IMCR valuations compare?

GLUE at $19.39 and IMCR at $28.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GLUE vs IMCR Valuation Comparison 2026 — Intrinsic Value Analysis

GLUE

Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$19.39

Last close

Models

12/13

Active

IMCR

Biological Products, (No Diagnostic Substances)

Immunocore Holdings plc

Quality

8.2

out of 10

Value Trap

SAFE

Price

$28.97

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GLUE Fair Value	GLUE Upside	IMCR Fair Value	IMCR Upside
Bayesian DCF	Intrinsic	$5.96	-69.3%	$14.45	-50.1%
Earnings Power Value	Intrinsic	$3.72	-80.2%	$28.68	+1.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GLUE vs IMCR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GLUE vs IMCR — Which Stock Is More Undervalued?

IMCR scores higher with a 8.2/10 quality rating vs GLUE's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Monte Rosa Therapeutics, Inc. (GLUE) and Immunocore Holdings plc (IMCR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GLUE currently trades at $19.39 with a QOC of 5.2/10, while IMCR trades at $28.97 with a QOC of 8.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).